Pyrosequencing ™ of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance

Pharmacogenomics

Volumn 8, Issue 12, 2007, Pages 1643-1660

  Skarke, Carsten ^a   Schuss, Patrick ^a   Kirchhof, Anja ^a   Doehring, Alexandra ^a   GeiBlinger, Gerd ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

COX 2; Genotype; Haplotype; Prostaglandin endoperoxide synthase 2; Pyrosequencing; SNP

Indexed keywords

CYCLOOXYGENASE 2; DNA; PTGS2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CAUCASIAN; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; DNA SEQUENCE; GENETICS; METHODOLOGY;

CYCLOOXYGENASE 2; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 37649006661     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.12.1643     Document Type: Article

References (62)

1. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231(25), 232-235 (1971).
2. Vane JR, Botting RM: Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 47(Suppl. 2) S78-S87 (1998).
3. Mamdani M, Rochon PA, Juurlink DN et al.: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325(7365), 624(2002).
4. Bresalier RS, Sandler RS, Quan H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11), 1092-1102 (2005).
5. Young D: Few options available for arthritis pain relief. FDA declines to approve Merck's Arcoxia. Am. J. Health Syst. Pharm. 64(10), 1020-1022 (2007).
6. Kearney PM, Baigent C, Godwin J et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332(7553), 1302-1308 (2006).
7. Szczeklik W, Sanak M, Szczeklik A: Functional effects and gender association of COX-2 gene polymorphism. G-765C in bronchial asthma. J. Allergy Clin. Immunol. 114(2), 248-253 (2004).
8. Cipollone F, Toniato E, Martinotti S et al.: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291(18), 2221-2228 (2004).
9. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA: Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin. Pharmacol. Ther. 79(5), 407-418 (2006).
10. Halushka MK, Halushka PV: Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypes. Clin. Pharmacol. Ther. 79(5), 404-406 (2006).
11. Skarke C, Reus M, Schmidt R et al.: The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin. Pharmacol. Ther. 80(6), 621-632 (2006).
12. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC: Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br. J. Cancer 90(9), 1760-1764 (2004).
13. Lee CR, North KE, Bray MS et al.: Cyclooxygenase polymorphisms and risk of cardiovascular events: the atherosclerosis risk in communities (ARIC) study. Clin. Pharmacol. Ther. 17(5), 349-358 (2007).
14. Abdullah L, Ait-Ghezala G, Crawford F et al.: The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease. Neurosci. Lett. 395(3), 240-243 (2006).
15. Campa D, Zienolddiny S, Maggini V et al.: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25(2), 229-235 (2004).
16. Vogel U, Christensen J, Wallin H et al.: Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat. Res. 617(1-2), 138-146 (2007).
17. Langsenlehner U, Yazdani-Biuki B, Eder T et al.: The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin. Cancer Res. 12(4), 1392-1394 (2006).
18. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O: A genetic polymorphism in prostaglandin synthase 2 (8473, T→C) and the risk of lung cancer. Cancer Lett. 226(1), 49-54 (2005).
19. Vogel U, Christensen J, Nexo BA et al.: Peroxisome profilerator-activated receptorgamma2 Pro12A1a, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28(2), 427-434 (2007).
20. Chan IH, Tang NL, Leung TF et al.: Association of prostaglandin-endoperoxide synthase 2 gene polymorphisms with asthma and atopy in Chinese children. Allergy 62(7), 802-809 (2007).
21. Nyren P, Lundin A: Enzymatic method for continuous monitoring of inorganic pyrophosphate synthesis. Anal. Biochem. 151(2), 504-509 (1985).
22. Ronaghi M, Uhlen M, Nyren P: A sequencing method based on real-time pyrophosphate. Science 281(5375), 363-365 (1998).
23. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P: Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem. 242(1), 84-89 (1996).
24. Hardy GH: Mendelian proportions in a mixed population. Science 28(49-50 (1908).
25. Lewontin RC: The interaction of selection and linkage II optimum models. Genetics 50 757-782 (1964).
26. Gaut BS, Long AD: The lowdown on linkage disequilibrium. Plant Cell 15(7), 1502-1506 (2003).
27. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
28. Panguluri RC, Long LO, Chen W et al.: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25(6), 961-966 (2004).
29. Cox DG, Pontes C, Guino E et al.: Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTCS2/COX2) and risk of colorectal cancer. Br. J. Cancer 91(2), 339-343 (2004).
30. Sanak M, Szczeklik W, Szczeklik A: Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J. Allergy Clin. Immunol. 116(1), 221-223 (2005).
31. Gorgoni B, Caivano M, Arizmendi C, Poli V: The transcription factor C/ EBPβ is essential for inducible expression of the COX-2 gene in macrophages but not in fibroblasts. J. Biol. Chem. 276(44), 40769-40777 (2001).
32. Papafili A, Hill MR, Brull DJ et al.: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22(10), 1631-1636 (2002).
33. Cui JG, Salehi-Rad S, Rogaeva E, Lukiw WJ: Characterization of a cyclooxygenase-2-765G→C promoter polymorphism in human neural cells. Neuroreport 16(6), 575-579 (2005).
34. O'Rourke J, Yuan R, DeWille J: CCAAT/enhancer-binding protein-δ (C/ EBP-delta) is induced in growth-arrested mouse mammary epithelial cells. J. Biol. Chem. 272(10), 6291-6296 (1997).
35. Lin HJ, Lakkides KM, Keku TO et al.: Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol. Biomarkers Prev. 11(11), 1305-1315 (2002).
36. Iwai N, Tago N, Yasui N et al.: Genetic analysis of 22 candidate genes for hypertension in the Japanese population. J. Hypertens 22(6), 1119-1126 (2004).
37. Gomez Lira M, Mazzola S, Tessari G et al.: Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br. J. Dermatol. 157(1), 49-57 (2007).
38. Mazzola S, Lira MG, Benedetti MD et al.: COX-2 promoter region polymorphisms in multiple sclerosis: lack of association of -765G>C with disease risk. Int. J. Immunogenet. 34(2), 71-74 (2007).
39. Kohsaka S, Volcik KA, Folsom AR et al.: Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study. Atherosclerosis (2007) (Epub ahead of print).
40. Shen J, Gammon MD, Terry MB et al.: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 8(6), R71 (2006).
41. Pereira C, Sousa H, Ferreira P et al.: -765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J. Gastroenterol. 12(34), 5473-5478 (2006).
42. Hegener HH, Diehl KA, Kurth T et al.: Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J. Thromb. Haemost. 4(8), 1718-1722 (2006).
43. Her MY, El-Sohemy A, Cornelis MC, Kim TH, Bae SC: Cyclooxygenase-2 polymorphisms and risk of systemic lupus erythematosus in Koreans. Rheumatol. Int. 27(1), 1-5 (2006).
44. Lee KH, Kim HS, El-Sohemy A et al.: Cyclooxygenase-2 genotype and rheumatoid arthritis. J. Rheumatol. 33(7), 1231-1234 (2006).
45. Colaizzo, D, Fofi L, Tiscia G et al.: The COX-2G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul. Fibrinolysis 17(2), 93-96 (2006).
46. Orbe J, Beloqui O, Rodriguez JA et al.: Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin. Chim. ACTA 368(1-2), 138-143 (2006).
47. Zhang X, Miao X, Tan W et al.: Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129(2), 565-576 (2005).
48. Brosens LA, Iacobuzio-Donahue CA, Keller JJ et al.: Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G>C COX-2 polymorphism. Clin. Cancer Res. 11(11), 4090-4096 (2005).
49. Ulrich CM, Whitton J, Yu JH et al.: PTGS2 (COX-2) -765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol. Biomarkers Prev. 14(3), 616-619 (2005).
50. Shi J, Misso NL, Duffy DL, Thompson PJ, Kedda MA: A functional polymorphism in the promoter region of the cyclooxygenase-2 gene is not associated with asthma and atopy in an Australian population. Clin. Exp. Allergy 34(11), 1714-1718 (2004).
51. Lee TS, Jeon YT, Kim JW et al.: Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in korean population. Ann. NY Acad. Sci. 1095 134-142 (2007).
52. Siezen CL, van Leeuwen AI, Kram NR et al.: Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 26(2), 449-457 (2005).
53. Valdes AM, Hart DJ, Jones KA et al.: Association study of candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis. Rheum. 50(8), 2497-2507 (2004).
54. Ma SL, Tang NL, Zhang YP et al.: Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese. Neurobiol. Aging (2007) (Epub ahead of print).
55. Hedelin M, Chang ET, Wiklund F et al.: Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int. J. Cancer 120(2), 398-405 (2007).
56. Park JM, Choi JE, Chae MH et al.: Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 6 70 (2006).
57. Sakoda LC, Gao YT, Chen BE et al.: Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 27(6), 1251-1256 (2006).
58. Ali IU, Luke BT, Dean M, Greenwald P: Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br. J. Cancer 93(8), 953-959 (2005).
59. Hu Z, Miao X, Ma H et al.: A common polymorphism in the 3′UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 48(1), 11-17 (2005).
60. Konheim YL, Wolford JK: Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum. Genet. 113(5), 377-381 (2003).
61. Fritsche E, Baek SJ, King LM et al.: Functional characterization of cyclooxygenase-2 polymorphisms. J. Pharmacol. Exp. Ther. 299(2), 468-476 (2001).
62. den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 15(1), 7-12 (2000).